Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 7/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 10/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
| ▸ | FPR1 | P21462 | 1/20 | 0.37 |
| ▸ | FPR3 | P25089 | 1/20 | 0.37 |
| ▸ | GPR183 | P32249 | 1/20 | 0.37 |
| ▸ | APLNR | P35414 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PPARD | Q03181 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25015298 | 0.89 | FFAR1 (0.43) | ACACBFFAR1CHRM2S1PR1FPR1 | |
| SCHEMBL24802692 | 0.79 | ACACB (0.51) | ACACBFFAR1FFAR4 | |
| SCHEMBL24802691 | 0.79 | ACACB (0.51) | ACACBFFAR1FFAR4 | |
| SCHEMBL25015185 | 0.77 | FFAR1 (0.40) | ACACBFFAR1CHRM2S1PR1FPR1 | |
| SCHEMBL25015146 | 0.74 | PPARD (0.40) | ACACBFFAR1MRGPRX4FFAR4MEN1 | |
| SCHEMBL25015299 | 0.73 | MAOB (0.43) | ACACBMEN1KMT2APPARA | |
| SCHEMBL25015143 | 0.73 | PPARA (0.41) | ACACBFFAR1MRGPRX4FFAR4PPARD | |
| SCHEMBL24802693 | 0.72 | FFAR4 (0.46) | ACACBFFAR1MRGPRX4FFAR4 | |
| SCHEMBL25015144 | 0.72 | FFAR1 (0.35) | ACACBFFAR1MEN1KMT2APPARD | |
| SCHEMBL24487378 | 0.69 | ACACB (0.50) | ACACBFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230042009-A1 | COMPOUND, COMPOSITION, CURED SUBSTANCE, OPTICALLY ANISOTROPIC BODY, OPTICAL ELEMENT, AND LIGHT GUIDE ELEMENT | FUJIFILM CORPORATION (JP) | 2023-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230042009-A1 | COMPOUND, COMPOSITION, CURED SUBSTANCE, OPTICALLY ANISOTROPIC BODY, OPTICAL ELEMENT, AND LIGHT GUIDE ELEMENT | SP1, C5, ZYX | ACACB 3334/4885FFAR1 2652/4885MRGPRX4 1017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.